title: Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab.
abstract: OBJECTIVE
  To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS).
  
  
  METHODS
  This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen.
  
  
  RESULTS
  Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.
authors.affiliation: a Department of Ophthalmology , University Vita-Salute, San Raffaele Hospital , Milan , Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Battaglia Parodi
authors.affiliation: b Fondazione G. B. Bietti per l'Oftalmologia, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) , Rome , Italy.
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Iacono
authors.affiliation: a Department of Ophthalmology , University Vita-Salute, San Raffaele Hospital , Milan , Italy.
authors.forename: Ilaria
authors.initials: I
authors.lastname: Zucchiatti
authors.affiliation: a Department of Ophthalmology , University Vita-Salute, San Raffaele Hospital , Milan , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D002833:Choroiditis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000080364:Multifocal Choroiditis; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab
keywords: Choroidal neovascularization; multiple evanescent white dot syndrome; ranibizumab